Andere Kunden interessierten sich auch für
![Nouvelles 4-hétéroaryl-Antipyrines comme inhibiteurs de la DPP-IV]( "Nouvelles 4-hétéroaryl-Antipyrines comme inhibiteurs de la DPP-IV")
Nouvelles 4-hétéroaryl-Antipyrines comme inhibiteurs de la DPP-IV23,99 €![Neuartige 4-Heteroaryl-Antipyrine als DPP-IV-Inhibitoren]( "Neuartige 4-Heteroaryl-Antipyrine als DPP-IV-Inhibitoren")
Neuartige 4-Heteroaryl-Antipyrine als DPP-IV-Inhibitoren35,90 €![Pharmaceutical Analysis of Some DPP-4 Inhibitors]( "Pharmaceutical Analysis of Some DPP-4 Inhibitors")
Pharmaceutical Analysis of Some DPP-4 Inhibitors45,99 €![Synthesis of Novel Heterocyclic Compounds and Studying as Inhibitors]( "Synthesis of Novel Heterocyclic Compounds and Studying as Inhibitors")
Synthesis of Novel Heterocyclic Compounds and Studying as Inhibitors19,99 €![Nuove 4-eteroaril-Antipirine come inibitori della DPP-IV]( "Nuove 4-eteroaril-Antipirine come inibitori della DPP-IV")
Nuove 4-eteroaril-Antipirine come inibitori della DPP-IV23,99 €![Novas 4-Heteroaril-Antipirinas como inibidores da DPP-IV]( "Novas 4-Heteroaril-Antipirinas como inibidores da DPP-IV")
Novas 4-Heteroaril-Antipirinas como inibidores da DPP-IV23,99 €![Nowye 4-geteroaril-antipiriny kak ingibitory DPP-IV]( "Nowye 4-geteroaril-antipiriny kak ingibitory DPP-IV")
Nowye 4-geteroaril-antipiriny kak ingibitory DPP-IV13,99 €
Type 2 diabetes mellitus is a progressive disease that affects almost 8.3% of global population. Regardless the availability of vast variety of oral hypoglycemics, only 36% of patients achieves proper glycemic control. With the advantage of low risk of hypoglycemia, DPP-IV attracted the attention of medicinal chemists as a new target for oral hypoglycemics. In this report, a lead compound 1, with antipyrine scaffold, was obtained, and its binding mode was calculated. Several derivatives with bridged nitrogenous heterocycles have been synthesized via multi-component reaction under controlled microwave heating conditions. The antidiabetic activity vs. DPP-IV protein was evaluated and compared with sitagliptin. Compounds with small or medium sized nitrogenous bridges were comparable with sitagliptin in term of DPP-IV inhibitory activity, potentially via targeting Glu203 and Glu204. The oral hypoglycemic activities of compounds with submicromolar IC50 values were further evaluated using diabetic mouse model.